Aligos Therapeutics, Inc.
ALGS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001799448
No open-market purchases or sales by Aligos Therapeutics, Inc. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.2M in total; HHLR Advisors (Hillhouse) is the only superinvestor holding it.
Q2 2024 vs. Q1 2024
How the institutions holding Aligos Therapeutics, Inc. changed between Q1 2024 and Q2 2024.
All holders in Q2 2024All holders in Q1 2024
| Measure | Q1 2024 | Q2 2024 | Change |
|---|---|---|---|
| Holders | 49 | 49 | 0 |
| Shares | 46.2M | 47.3M | +1.08M (+2.3%) |
| Value | $45.3M | $16.6M | −$28.7M (−63.5%) |
New holders (8)
Institutions that held Aligos Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Woodline Partners LP | 531,204 | $185.9K | 0.00% |
| Alyeska Investment Group, L.P. | 284,233 | $99.5K | 0.00% |
| LMR Partners LLP | 50,000 | $17.5K | 0.00% |
| Prudential Financial Inc | 19,600 | $6.86K | 0.00% |
| Jane Street Group, LLC | 13,666 | $4.78K | 0.00% |
| HighTower Advisors, LLC | 10,000 | $4.00K | 0.00% |
| Virtu Financial LLC | 12,306 | $4.00K | 0.00% |
| Advisor Group Holdings, Inc. | 5,500 | $1.93K | 0.00% |
Sold out (8)
Institutions that held Aligos Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.
| Institution | Shares, Q1 2024 | Value, Q1 2024 |
|---|---|---|
| Altitude Crest Partners Inc. | 2,844,681 | $2.79M |
| Bridgeway Capital Management, LLC | 92,000 | $90.2K |
| Atom Investors LP | 34,173 | $33.5K |
| Procyon Private Wealth Partners, LLC | 20,000 | $19.6K |
| Vontobel Holding Ltd. | 12,500 | $12.3K |
| Financial Advocates Investment Management | 10,000 | $9.80K |
| Total Clarity Wealth Management, Inc. | 10,000 | $9.80K |
| Wells Fargo & Company | 298 | $292 |